Company: RNGE
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001343
Chunk: 838

Company: RANGE IMPACT, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 9
Chunk 838
---
  
     447,800 

    Patricia Missal, Chief Financial Officer (principal
    financial officer) (3) 
     Year
                                            Ended 12/31/24  
     267,750  
     95,000  
     362,750 

     Year
                                            Ended 12/31/23  
     156,750  
     -  
     156,750 

    Richard McKilligan, Former Chief Financial
    Officer (former principal financial officer) (4) 
     Year
                                            Ended 12/31/24  
     45,000  
     -  
     45,000 

     Year
                                            Ended 12/31/23  
     180,000  
     -  
     180,000 

    Dr. Brandon Zipp, Former Chief Science Officer
    (5) 
     Year
                                            Ended 12/31/24  
     45,000  
     -  
     45,000 

     Year
                                            Ended 12/31/23  
     180,000  
     -  
     180,000 

(1)
The method used and the assumptions made to calculate the fair value of option awards included in this table are described in Footnote
6 of the financial statements and the accompanying notes for the years ended December 31, 2024 and December 31, 2023 appearing elsewhere
in this Annual Report.

(2)
Based on the fair value of an option to purchase 1,000,000 shares of common stock with an exercise price of $0.212 per share, granted
in December 2023.

(3)
Ms. Missal was appointed to the CFO role on April 25, 2024. Previously she served as Controller. The value of the option award is based on the fair value of an option
to purchase 250,000 shares of common stock with an exercise price of $0.38 per share, granted in April 2024.

(4)
Mr. McKilligan moved to serve as CFO of Graphium Biosciences effective April 25, 2024 and remained with that entity until it was spun
off in September 2024.

(5)
Dr. Zipp moved to serve as Chief Science Officer of Graphium Biosciences effective